Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
Login Archives Your Team About Us FAQ
[mmpazkzone name="azk58712-mobile-nav" network="9794" site="307044" id="222451" type="5"]
  • Subscribe
Enter stock ticker or keyword
×
[mmpazkzone name="azk58712-mobile-sticky" network="9794" site="307044" id="222451" type="5"]
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Stocks
Stocks: ILMN

This Tech Stock Could Double Your Money in Less Than 3 Years

By Money Morning Staff Reports, Money Morning • November 6, 2018

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

The technology behind next-generation sequencing (NGS) might be complicated, but the potential to make boatloads of money from it is quite simple.

In September, scientists used cutting-edge techniques to insert genes in common pigeons that will allow them to alter the pigeons' offspring with DNA from the extinct passenger pigeon.

And bringing back a pigeon that went extinct in 1914 is just the start of the breakthroughs in the NGS market. Eventually, the tech could help cure cancer and eliminate Alzheimer's.

handshakeThe NGS market was valued at $4.62 billion in 2015, and it's expected to skyrocket 362% to $21.4 billion by 2025, according to Grand View Research.

The profit opportunity is going to be huge, but finding the best medical tech stock in this complicated market isn't easy.

There's a lot of hype around gene-editing companies, but there is one that's more deserving of your hard-earned money.

That's why we brought in an expert.

Medical Breakthrough: A tiny $6 million company just won a stunning patent verdict, setting up an explosive 28,700% sales surge in the next 18 months. This stock could soar - click here for details...

Money Morning Defense and Tech Specialist Michael Robinson is a 30-year veteran of tech markets with a Rolodex of Silicon Valley CEOs.

With the 362% projected growth in the NGS market over the next seven years, Robinson says you can ride that soaring market with one tech stock that could double...

The Top Tech Stock in the Growing $21.4 Billion NGS Market

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Robinson says there are a lot of ways to play this new medical market that offer a high reward, but they are risky.

Instead, he suggests putting money in Illumina Inc. (NASDAQ: ILMN).

Robinson calls this a "pick and shovel" play.

Instead of investing in gene-editing companies directly, a pick-and-shovel play would be to invest in an equipment supplier. The equipment is critical in allowing scientists to reach massive new breakthroughs.

That's where Illumina comes in.

It provides products for genomics (structure, function, evolution, and mapping of genomes) and sequencing kits.

And as more medical companies race to be the first to uncover breakthroughs, ILMN equipment sales should skyrocket.

More revenue means more demand for the stock, which can send share prices higher.

Over the next 12 months, financial firm Cowen & Co. expects the ILMN stock price to climb to $400 per share.

From today's (Nov. 6) price of $322.60, that's a potential profit of 23.99%.

However, that's just the start of how much money you could make...

"Over the past three years they [earnings per share] have grown by an average 13%, but they soared by 74% in the most recent quarter. Now we use what I call my Doubling Calculator to divide the compound profit growth rate of 36% into the number 72. We find that any Illumina shares you buy today should double in 2.7 years," Robinson said on Oct. 30.

Don't Miss Michael's Next Potential Triple-Digit Win

Michael's paid-up Radical Technology Profits subscribers just had the chance to book a 400% gain on a cutting-edge "fintech" firm placing itself at the vanguard of cryptocurrency-based transactions.

That massive win comes less than a week after subscribers saw a 106% gain on an aggressive mid-cap biotech.

If you missed out on these profits, there's still time to get in on the next moneymaking opportunity: a tiny $6 million company poised to remake medicine as we know it.

With 40 registered patents and 500 patents pending, it's positioned to disrupt every aspect of the $3 trillion healthcare market.

And now a shocking verdict in a bitter court battle could trigger a 28,700% sales surge.

To get all the details - and to learn how you can get all of Michael's recommendations - click here now...

Follow Money Morning on Facebook, Twitter, and LinkedIn.

ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us How Money Morning Works FAQs Contact Us Search Article Archive Your Team Text Messaging Terms of Use
TOPICS
AI Investing Best Stocks to Buy Stock Forecasts Stocks to Sell Now Technology Stocks Best REITs to Buy Now IPO Stocks Penny Stocks Dividend Stocks Cryptocurrencies How to Trade Options Best Trades to Make Now Options Trading Strategies Weekly Trade Recommendations Income Investing Guide Retirement Articles Special Investing Reports Meet Our Experts
PREMIUM SERVICES
Money Map Press Home Fast Fortune Club Microcurrency Trader Rocket Wealth Initiative Quantum Data Profits Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information